Dr. Fine on Therapeutic Metabolic Targets in Brain Cancer

Howard Fine, MD
Published: Saturday, Nov 19, 2016



Howard Fine, MD, Weill Cornell Medicine, discusses the importance of novel metabolic targets, such as IDH mutations, in the field of neuro-oncology. Mutations in IDH result in an altered metabolic state, in which production of the oncometabolite 2-HG is increased. This leads to dysregulation of genetic and epigenetic processes, leading to oncogenesis.

The metabolism of tumor tissue is very different from that in other tissue. That difference offers an area that can be used to develop more therapeutic targets. Although it is unlikely that another IDH-type mutations will be discovered, the differences between tumors and normal tissue are ideal targets, as inhibition of these markers would have less of an impact on healthy tissue, Fine notes

Tumor metabolism is very complex series of pathways, Fine notes. As the science advances, more knowledge will emerge on the molecular basis for the metabolic difference between tumor tissue and other tissue.

<<< View more from the 2016 SNO Annual Meeting


Howard Fine, MD, Weill Cornell Medicine, discusses the importance of novel metabolic targets, such as IDH mutations, in the field of neuro-oncology. Mutations in IDH result in an altered metabolic state, in which production of the oncometabolite 2-HG is increased. This leads to dysregulation of genetic and epigenetic processes, leading to oncogenesis.

The metabolism of tumor tissue is very different from that in other tissue. That difference offers an area that can be used to develop more therapeutic targets. Although it is unlikely that another IDH-type mutations will be discovered, the differences between tumors and normal tissue are ideal targets, as inhibition of these markers would have less of an impact on healthy tissue, Fine notes

Tumor metabolism is very complex series of pathways, Fine notes. As the science advances, more knowledge will emerge on the molecular basis for the metabolic difference between tumor tissue and other tissue.

<<< View more from the 2016 SNO Annual Meeting

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x